Phenformine [Inn-French] en es it fr

Phenformine [Inn-French] Brand names, Phenformine [Inn-French] Analogs

Phenformine [Inn-French] Brand Names Mixture

  • No information avaliable

Phenformine [Inn-French] Chemical_Formula


Phenformine [Inn-French] RX_link

No information avaliable

Phenformine [Inn-French] fda sheet

Phenformine [Inn-French] msds (material safety sheet)

Phenformine [Inn-French] Synthesis Reference

Shapiro, Freedman, U.S. pats. 2,961,377, 3,057,780 (1960, 1962 both to U.S.V.)

Phenformine [Inn-French] Molecular Weight

205.26 g/mol

Phenformine [Inn-French] Melting Point

175-178 oC

Phenformine [Inn-French] H2O Solubility

210 mg/mL

Phenformine [Inn-French] State


Phenformine [Inn-French] LogP


Phenformine [Inn-French] Dosage Forms

No information avaliable

Phenformine [Inn-French] Indication

For the reatment of type II diabetes mellitus.

Phenformine [Inn-French] Pharmacology

Used to treat diabetes, phenformin is a biguanide (contains 2 guanidino groups) hypoglycemic agent with actions and uses similar to those of metformin (Glucophage). Both drugs work by (1) decreasing the absorption of glucose by the intestines, (2) decreasing the production of glucose in the liver, and by (3) increasing the body's ability to use insulin more effectively. More specifically, phenformin improves glycemic control by improving insulin sensitivity. Phenformin is generally considered to be associated with an unacceptably high incidence of actic acidosis. In general biguanides should be used only in stable type II diabetics who are free of liver, kidney and cardiovascular problems and who cannot be controlled with diet.

Phenformine [Inn-French] Absorption

No information avaliable

Phenformine [Inn-French] side effects and Toxicity

No information avaliable

Phenformine [Inn-French] Patient Information

No information avaliable

Phenformine [Inn-French] Organisms Affected

Humans and other mammals